Ozempic and Mounjaro are both injectable weight-loss and diabetes medications, but they work slightly differently: Ozempic contains semaglutide (a GLP-1 drug), while Mounjaro contains tirzepatide, which acts on two hormone pathways and tends to produce greater weight loss. This guide compares how they work, their results in clinical trials, dosing, side effects, and how to choose between them.
Ozempic vs Mounjaro at a glance
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| How it works | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Weight-loss brand of the same drug | Wegovy | Zepbound |
| How often | Once a week, under the skin | Once a week, under the skin |
| Starting dose | 0.25 mg | 2.5 mg |
| Maximum dose | 2 mg (2.4 mg as Wegovy) | 15 mg |
| Average weight loss in major trials | About 15% (semaglutide 2.4 mg) | About 20% (tirzepatide 15 mg) |
| Main side effects | Nausea, diarrhoea or constipation, reduced appetite; mostly when starting or increasing the dose | |
Ozempic vs Mounjaro: the key difference
The active ingredients are what set them apart. Ozempic (semaglutide) mimics GLP-1, a gut hormone that curbs appetite, slows stomach emptying, and improves blood-sugar control. Mounjaro (tirzepatide) mimics GLP-1 and a second hormone, GIP. This dual action appears to strengthen the effect on appetite and metabolism, and in head-to-head trials it has produced greater average weight loss than semaglutide alone. Both are weekly injections originally developed for type 2 diabetes and now widely used for weight management. For how these drugs drive weight loss biologically, see how semaglutide works for weight loss.
Tirzepatide vs semaglutide: weight-loss results
The large clinical trials give a useful picture of what each drug can do when combined with diet and exercise advice:
- Semaglutide 2.4 mg (STEP 1 trial): adults without diabetes lost an average of about 15% of body weight over 68 weeks.
- Tirzepatide 15 mg (SURMOUNT-1 trial): adults without diabetes lost an average of about 21% of body weight over 72 weeks.
- Head to head (SURMOUNT-5 trial): when the two were compared directly in adults with obesity, tirzepatide led to an average loss of about 20% of body weight versus about 14% with semaglutide over 72 weeks.
These are averages. Individual responses vary widely: some people lose far more, some less, and both drugs are highly effective compared with older options. In people with type 2 diabetes, weight loss on either drug is usually somewhat smaller. The right choice is not simply “the stronger one”; it depends on your starting point, tolerance, other health conditions, and how your body responds.
Dosing: how each medication is started
Both drugs start at a low dose that is increased step by step, usually every four weeks. Going slowly is the single most effective way to limit side effects.
- Ozempic: 0.25 mg weekly for four weeks, then 0.5 mg. If needed, the dose is increased to 1 mg and then 2 mg. (Wegovy, the weight-loss version, goes up to 2.4 mg.)
- Mounjaro: 2.5 mg weekly for four weeks, then 5 mg. If needed, the dose is increased in 2.5 mg steps (7.5, 10, 12.5 mg) up to a maximum of 15 mg.
Many people reach their goals without going to the maximum dose. Your doctor will hold or slow the increases if side effects are troublesome.
Side effects of Ozempic and Mounjaro
Both share a similar side-effect profile, mostly gastrointestinal and usually strongest when starting or increasing the dose:
- Nausea, and sometimes vomiting
- Diarrhoea or constipation
- Reduced appetite and early fullness
- Occasional fatigue, bloating or indigestion early on
These typically ease as the body adjusts. Eating smaller meals, stopping when full, limiting fatty and fried food, and drinking enough water all help. Less common but more serious risks include pancreatitis, gallbladder problems such as gallstones, and dehydration from persistent vomiting or diarrhoea, which is why both drugs should be used under medical supervision. Some people also notice temporary hair shedding during rapid weight loss (see GLP-1 hair loss).
Who should not use Ozempic or Mounjaro
Neither medication is suitable for everyone. Tell your doctor before starting if you have:
- A personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2)
- A history of pancreatitis
- Severe gastrointestinal disease, such as gastroparesis
- Diabetic eye disease (retinopathy), which needs monitoring when blood sugar improves quickly
- Any planned surgery, as these drugs slow stomach emptying and may need to be paused beforehand
Neither drug should be used during pregnancy. Your doctor will also review other medications, particularly insulin or sulfonylureas, which can increase the risk of low blood sugar when combined.
Protecting muscle while losing weight
A meaningful share of the weight lost on GLP-1 medications can come from muscle rather than fat, especially if protein intake is low and there is no strength training. To protect muscle, aim for adequate protein at every meal and do resistance training two to three times a week. For men, low testosterone makes muscle loss more likely, so it is worth checking levels before or during treatment. Pairing weight-loss medication with testosterone optimisation can help preserve muscle while losing fat. See also Ozempic and testosterone.
What happens when you stop?
Weight regain after stopping is common with both drugs. In follow-up trials, people who switched to placebo after successful weight loss regained a large part of the weight within a year, while those who continued kept losing or maintained their loss. That does not mean treatment has to be lifelong for everyone, but it does mean stopping should be planned with your doctor: tapering the dose and building eating, training and sleep habits that can hold the result.
Can you switch from Ozempic to Mounjaro?
Yes. Switching is common, usually because of a weight-loss plateau, side effects, or availability. You do not normally take both at the same time. Your doctor will typically start Mounjaro at a dose that matches how far you were on Ozempic, often starting the new medication a week after your last Ozempic dose. Switching should always be supervised rather than self-managed.
How to choose between them
The decision should be made with a clinician based on your weight-loss goals, blood sugar, tolerance, other medications, cost, and availability. As a rough guide:
- Mounjaro may suit people who want the largest average weight loss, or who have plateaued on semaglutide.
- Ozempic has a longer track record and strong evidence for heart and kidney protection in people with type 2 diabetes. It is also more widely available.
Many people start on one and adjust based on response and side effects. Crucially, these medications work best as part of a supervised programme alongside nutrition and activity, not as a standalone fix.
Frequently asked questions
Is Mounjaro stronger than Ozempic?
On average, yes, for weight loss. In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20% average weight loss versus about 14% for semaglutide. “Stronger” also tends to mean similar or slightly more gastrointestinal side effects at higher doses, and individual results vary.
Is tirzepatide the same as semaglutide?
No. Both act on the GLP-1 receptor, but tirzepatide also acts on the GIP receptor. They are different molecules from different manufacturers.
How fast will I lose weight?
Weight loss is usually gradual in the first one to two months while the dose is still low, then picks up. Most of the loss happens over the first six to twelve months.
Do I need a prescription?
Yes. Both are prescription medications and should be started and monitored by a doctor. Be wary of unregulated or “compounded” versions sold online, which may not contain what the label says. If you are in Jakarta, see how expats get a Mounjaro prescription in Jakarta.
The bottom line
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both effective GLP-1-based weight-loss medications. Mounjaro’s dual action often yields more weight loss, but the best choice is individual and should be made with a doctor. Side effects are mostly mild and gastrointestinal, muscle should be protected along the way, and supervision matters, both when starting and when stopping.
At Boost Health Clinic, we provide doctor-supervised medical weight-loss programmes using GLP-1 medications. To find the right option for you, book a consultation. If you are in Bali, see how we prescribe and monitor Ozempic and Mounjaro in Bali.
In Jakarta? See our page on Mounjaro in Jakarta.
Related: GLP-1 weight loss medications in Indonesia: how to start Mounjaro or Ozempic with a doctor.
This article is general information and not medical advice. All treatments mentioned require assessment by a qualified doctor.